Foster City, CA, February 21, 2008 –Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced today that PDL Biopharma (“PDL”) has signed an agreement with Entelos to conduct in silico research and “virtual clinical trials”. The research is expected to take two months and is focused on identifying primary endpoints, patient types, and optimal doses to support one of PDL’s antibody development programs.
